Role of Different Grades of Polyethylene Glycols (PEG 200 to PEG 20000)
in the Pharmaceutical Industry
WHO-GMP Certified | USP / EP / BP / IP Compliant | Excipact | FSSAI Certified PEG 200 – PEG 20000 | 14 Grades Available
Introduction
Polyethylene glycols (PEGs) represent one of the most versatile and widely utilized families of excipients in the modern pharmaceutical industry. Chemically defined as polymers of ethylene oxide, PEGs are synthesized through ring-opening polymerization, yielding linear or branched polyether chains of varying molecular weights.
The number appended to the PEG designation such as PEG 200, PEG 400, or PEG 6000 directly corresponds to the average molecular weight in daltons (Da). This molecular weight fundamentally governs the physical state, viscosity, water solubility, and pharmaceutical function of each grade.
PEGs are non-ionic, biocompatible, and Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration (FDA). They are listed in major pharmacopoeias including USP, British Pharmacopoeia (BP), and European Pharmacopoeia (Ph. Eur.). From low-molecular-weight liquid grades used in injectable formulations to high-molecular-weight waxy solids employed in tablet coatings and suppository bases, PEGs offer formulators a uniquely scalable toolkit.
Physical Classification of PEG Grades
PEGs are broadly classified into three physical states based on molecular weight at room temperature:
Low molecular weight PEGs are clear, colorless, hygroscopic liquids with excellent water miscibility. They serve primarily as co-solvents, injectable vehicles, and ophthalmic agents. Their small molecule size facilitates rapid distribution and renal clearance.
PEG 200
The lowest MW pharmaceutical-grade PEG. Clear, colorless, hygroscopic liquid with a low viscosity of approximately 4.3 centistokes. Exceptional water miscibility makes it an outstanding co-solvent for drugs with limited aqueous solubility. Approved for intravenous use in injectable vitamins and poorly soluble actives.
• Injectable formulations (IV approved)
• Plasticizer in film coatings
• Humectant in topical preparations
• Co-solvent for BCS Class II and IV drugs
PEG 300
Shares characteristics with PEG 200 but offers marginally greater viscosity and improved solubilization capacity for hydrophobic drugs. Widely utilized in ophthalmic solutions as a lubricant and viscosityenhancing agent, critical for dry eye syndrome treatments.
• Ophthalmic lubricant drops (dry eye)
• Oral liquid vehicle
• Taste-masking agent
• Topical gel spreadability modifier
PEG 400
The most extensively used pharmaceutical-grade PEG the formulator's first choice among liquid PEGs. Its balance of hydrophilicity, viscosity, chemical stability, and regulatory acceptability make it indispensable across a broad spectrum of dosage forms. Used parenterally in formulations of lorazepam and diazepam.
• Softgel capsule fill vehicle
• SEDDS / self-emulsifying drug delivery systems
• Ophthalmic lubricant (0.2–1%)
• Parenteral IV co-solvent (approved)
PEG 600
Bridges the gap between freely flowing liquid grades and semi-solid higher-weight PEGs. Elevated viscosity makes it suitable for softgel capsule fills where a more viscous matrix is desired to slow drug release. Used in combination with higher-MW PEGs to create blended ointment bases with adjustable hardness.
• Softgel viscous fill matrix
• Ointment and cream consistency modifier
• Humectant in dermatological formulations
• Blended ointment base modifier
Medium Molecular Weight PEGs (PEG 800 – PEG
1500): Semi-Solid to Waxy Grades
Medium molecular weight PEGs transition from paste-like semi-solids to firm waxy solids. Their melting points near body temperature make them exceptionally valuable for suppository manufacturing and modified-release tablet systems.
PEG 800
Exists at room temperature as a soft, paste-like semi-solid the transition between liquid and solid PEG grades. Valuable in semi-solid dosage forms such as ointments and creams for texture, spreadability, and water-washability. Used in polyethylene glycol ointment bases as defined in pharmacopeial standards.
• Semi-solid ointment bases
• Suppository formulation modifier
• Rheology fine-tuner for topical bases
• Pharmacopeial PEG ointment base
PEG 1000
A soft, waxy solid with a melting point in the range of 37–40°C coincidentally close to body temperature. Exceptionally useful in suppository manufacturing where the excipient must melt upon rectal or vaginal insertion. Also serves as a meltable binder and lubricant in hot-melt extrusion processes.
• Suppository base (rectal / vaginal)
• Hot-melt extrusion meltable binder
• Meltable tablet lubricant
• Film-forming tablet coating agent
PEG 1450
A firm, waxy solid widely used as a tablet lubricant in direct compression formulations where magnesium stearate levels may need to be minimized or avoided for compatibility reasons. Provides excellent ejection and anti-sticking properties without significantly retarding drug dissolution.
• Tablet lubricant (direct compression)
• Meltable lubricant alternative to magnesium stearate
• Aqueous film coating plasticizer
• Immediate and modified-release tablet systems
PEG 1500
Closely mirrors PEG 1450 in physical properties. A recognized pharmacopoeial excipient for suppository bases, particularly water-soluble suppositories where PEG blends replace traditional cocoa butter or triglyceride bases. Allows precise engineering of suppository hardness, melting point, and drug-release kinetics.
High molecular weight PEGs are hard waxy solids to fine white powders. They serve as tablet binders, sustained-release matrix formers, coating plasticizers, lyophilization excipients, and PEGylation agents for biopharmaceuticals.
PEG 3350
Holds a unique distinction it is the Active Pharmaceutical Ingredient (API) in several widely prescribed laxative products, functioning as an osmotic agent. Essentially non-absorbed from the GI tract due to its large molecular size, it retains water in the intestinal lumen by osmotic action, facilitating bowel movement. Also a critical plasticizer in HPMC-based aqueous film coatings.
One of the most frequently used solid-grade PEGs in tablet and pellet manufacturing. Acts as binder in wet granulation and melt granulation, carrier matrix and plasticizer in hot-melt extrusion (HME), and pore-former in ethylcellulose-based sustained-release coatings where dissolution of PEG creates micropores regulating drug diffusion.
• Tablet binder (wet and melt granulation)
• HME solid dispersion carrier
• Pore-former in ethylcellulose sustained-release coatings
• Tablet lubricant with good dissolution profile
PEG
6000
A hard, flaky white solid with a melting point of approximately 55–63°C. Valuable in thermal manufacturing processes. Used as tablet lubricant in direct compression, binder in melt granulation, sustained-release matrix former, and to form eutectic or solid solution systems with drugs for solubility enhancement.
• Direct compression tablet lubricant
• Melt granulation binder and matrix
• Eutectic solid solutions for solubility enhancement
• Fast-dissolving drug delivery systems
PEG 8000
Offers properties similar to PEG 6000 but with higher molecular weight and hardness. Serves as a sustained-release matrix in tablets, plasticizer in modified-release film coatings, and cryoprotectant and bulking agent in pharmaceutical freeze-drying (lyophilization) for proteins and biopharmaceuticals.
• Sustained-release tablet matrix
• Modified-release film coating plasticizer
• Lyophilization cryoprotectant and bulking agent
• Biopharmaceutical protein stabilizer
PEG 10000
At 10,000 Da, PEG begins to exhibit characteristics increasingly relevant to biopharmaceutical applications. Used in formulation as a film-forming agent, binder, and high-molecular-weight plasticizer. In advanced drug delivery systems including matrix tablets and multiparticulate systems, contributes to zero-order or near-zero-order drug release profiles.
• Advanced matrix tablet (zero-order release)
• Biologics purification precipitation aid
• Film-forming agent and high-MW plasticizer
• Cryoprotectant in lyophilization (superior for large proteins)
PEG 20000
The highest MW grade occupying a specialized niche in advanced and biopharmaceutical applications. Extensively used in PEGylation the covalent attachment of PEG chains to therapeutic proteins, peptides, and small molecules to improve pharmacokinetic profiles. PEGylation significantly extends plasma half-life through reduced renal filtration, decreased immunogenicity, and protection from proteolytic degradation.
• Reduced immunogenicity and proteolytic protection
Application Summary by Dosage Form
The following table maps recommended PEG grades to pharmaceutical dosage forms and their primary excipient functions:
Dosage Form
Injectable / Parenteral
Ophthalmic Solutions
Oral Liquid / Drops
Softgel Capsules
Topical / Transdermal
Ointments & Creams
Suppositories
Tablet Lubrication
Tablet Binding / Granulation
Film Coating
Sustained / Modified Release
Laxative (API)
Lyophilization / Biologics
PEGylation / Bioconjugation
Recommended PEG Grades
PEG 200, PEG 300, PEG 400
PEG 300, PEG 400
PEG 300, PEG 400, PEG 600
PEG 400, PEG 600
PEG 200 – PEG 1000
PEG 400, PEG 600, PEG 800
PEG 1000, PEG 1450, PEG 1500
PEG 1450, PEG 4000, PEG 6000
PEG 4000, PEG 6000, PEG 8000
PEG 1450, PEG 3350, PEG 4000
PEG 6000, PEG 8000, PEG 10000
PEG 3350, PEG 4000
PEG 8000, PEG 10000
PEG 10000, PEG 20000
Primary Function
Co-solvent, IV-approved solubilizer
Lubricant, viscosity-enhancer, dry eye
Co-solvent, taste-masking, vehicle
Fill matrix, SEDDS vehicle
Vehicle, penetration enhancer, humectant
Hydrophilic base, water-washable ointment
Meltable suppository base (~37–40°C)
Meltable lubricant, anti-adherent
Binder in wet/melt granulation, HME
Plasticizer for HPMC/acrylic coatings
Matrix former, pore-former in coatings
Osmotic agent (bowel preparation)
Cryoprotectant, bulking agent, stabilizer
Extend half-life of therapeutic proteins
Regulatory Status & Safety Considerations
Pharmacopoeial Listings
All PEG grades discussed in this document are listed in major international pharmacopoeias and carry GRAS status from the U.S. FDA. They are approved for oral, topical, rectal, and parenteral use, with specific concentration limits defined in the FDA Inactive Ingredient Database (IID).
Safety Considerations
PEGs are generally considered non-toxic and well-tolerated. However, high-dose parenteral administration of low-molecular-weight PEGs (particularly PEG 400) has been associated with hyperosmolarity and renal toxicity in certain patient populations, necessitating careful dose calculations.
Contact hypersensitivity and anaphylactic reactions to PEGs have been reported with increasing frequency, particularly in the context of PEGylated vaccines and injectable formulations. The FDA and EMA have issued guidance recommending appropriate labeling and allergy screening for high-dose PEG-containing injectables.
Emerging Applications & Future Perspectives
PEG Hydrogels
Crosslinked PEG networks are being explored as injectable depots for sustained protein delivery, wound healing scaffolds, and tissue engineering matrices.
Lipid Nanoparticles (LNP)
PEGylated lipids serve as steric stabilizers in mRNA vaccine LNP platforms preventing aggregation and extending circulation time. The architecture of PEG used profoundly impacts nanoparticle stability, cellular uptake, and immunogenicity.
Stimuli-Responsive PEG Systems
pH-, temperature-, or enzyme-responsive PEG coatings that detach at tumor sites are under active research for targeted oncology drug delivery with minimal systemic toxicity.
PEG Dendrimers & Block Copolymers
PEG-dendrimer hybrids and PEG-polypeptide block copolymers combine the biocompatibility of PEG with the functional versatility of dendritic architectures for precision drug delivery.
Pharcogol® — Complete Product Range
Pharcogol® is Pharcos Speciality's premium range of Polyethylene Glycols (PEGs) manufactured in WHO GMP-certified facilities with exceptional purity, consistency, and full compliance with USP, EP, BP, and IP pharmacopoeias. Available from PEG 200 to PEG 20000 liquid, semi-solid, and solid grades for every formulation need
